CL vs TEVA vs BBWI Stock Comparison

Colgate Palmolive, Teva Pharmaceutical Industries and Bath & Body Works Prices as of Nov 13, 2026 Peers: Industry group
CL Colgate Palmolive Co
$99.67 +7.4% 1M +26.5% 1Y
Market cap
$80.86B
P/E
39.4x
Revenue (TTM)
$21.28B
Div. yield
0.02%
Personal Care Products Consumer Staples
3 wins
BBWI Bath & Body Works, Inc.
$21.38 +12.9% 1M -2.8% 1Y
Market cap
$4.21B
P/E
4.1x
Revenue (TTM)
$11.78B
Div. yield
-0.07%
Personal Care Products Consumer Staples
6 wins

Head to Head

11 decided of 12

Bath & Body Works leads on 6 of the 12 questions below (Bath & Body Works 6, Colgate Palmolive 3, Teva Pharmaceutical Industries 2). Which ones matter depends on what you are buying for; a cheap multiple and slow growth often come together.

QuestionCLTEVABBWILeader
Larger companyMarket capitalisation $80.86B $50.16B $4.21B CL
Cheaper on earningsLower P/E, profitable companies only 39.4x 99.1x 4.1x BBWI
Cheaper on forward earningsLower price / next fiscal year consensus EPS 26.2x 22.7x 7.6x BBWI
Faster revenue growthRevenue growth, trailing twelve months +5.9% +2.7% +92.8% BBWI
More profitableNet margin, trailing twelve months 9.6% 2.9% 8.7% CL
Better return on capitalReturn on invested capital 27.6% 5.9% 68.8% BBWI
Less leveragedLower net debt / EBITDA 1.6x 5.2x 1.3x BBWI
Higher dividend yieldTrailing dividend yield 0.02% 0.00% -0.07% –
Better 1-year returnPrice return, last 12 months +26.5% +74.4% -2.8% TEVA
Better 5-year returnAnnualised price return, 5 years +5.0%/yr +36.2%/yr -22.2%/yr TEVA
Less volatileAnnualised volatility, 1 year 23.5% 33.4% 62.1% CL
Higher overall scoreMean of the five percentile scores vs peers 61/100 62/100 69/100 BBWI

Percentile Scorecard

CLTEVABBWI

Each axis is the mean percentile of its metrics against the company's industry group. 100 is the best in the group, 50 the middle.

Scores by Axis

AxisCLTEVABBWI
Valuation 54 #26 of 55 82 #120 of 660 98 #2 of 55
Growth 61 #21 of 52 68 #201 of 619 69 #17 of 52
Profitability 98 #2 of 50 86 #87 of 595 94 #4 of 50
Financial Health 43 #34 of 59 11 #608 of 683 45 #33 of 59
Shareholder Returns 52 #16 of 32 – 39 #20 of 32
Overall 61 62 69
  • CL ranked among 60 companies in Household and Personal Products
  • TEVA ranked among 695 companies in Pharmaceuticals and Biotechnology
  • BBWI ranked among 60 companies in Household and Personal Products

Price Performance

Price return, split-adjusted, before dividends. Click a name to hide or show it.

Returns

PeriodCLTEVABBWISPY
1 month +7.4%+9.3%+12.9% -2.0%
3 months +8.4%+21.1%+10.1% -2.8%
6 months +13.1%+29.9%+25.1% +2.0%
Year to date +26.1%+42.7%+6.5% +10.6%
1 year +26.5%+74.4%-2.8% +12.2%
3 years +30.0%+399.9%-32.1% +68.1%
3 years, per year +9.2%+71.0%-12.1% +18.9%
5 years +27.7%+368.3%-71.4% +61.4%
5 years, per year +5.0%+36.2%-22.2% +10.1%
10 years +47.8%+9.6%-61.8% +248.5%
10 years, per year +4.0%+0.9%-9.2% +13.3%

Risk

MeasureCLTEVABBWISPY
Volatility, 1Y 23.5%33.4%62.1% 13.6%
Downside volatility, 1Y 21.8%27.5%64.1% 13.9%
Beta vs S&P 500, 1Y -0.100.591.35 1.00
Return / volatility, 1Y 1.132.23-0.04 0.90
Max drawdown, 5Y -31.1%-43.7%-81.1% -25.4%
From 52-week high 0.0%0.0%-13.3% -3.2%
52-week high $99.67$44.54$24.67 $779.14
52-week low $76.11$24.21$14.85 $631.97

Valuation History

Weekly multiples on trailing twelve-month fundamentals. Negative or extreme readings (a loss year, a collapsed denominator) are left out so the chart stays readable.

MultipleCLTEVABBWI
P/E now vs peer median 38.7xmedian 21.1x 102.6xmedian 17.0x 4.5xmedian 21.1x
P/S now vs peer median 3.7xmedian 2.2x 3.0xmedian 8.4x 0.4xmedian 2.2x
EV/EBITDA now vs peer median 22.5xmedian 14.0x 26.7xmedian 14.6x 3.3xmedian 14.0x
P/FCF now vs peer median 20.9xmedian 17.3x 42.0xmedian 19.0x 3.0xmedian 17.3x
P/B now vs peer median 123.8xmedian 1.9x 6.5xmedian 2.0x -4.1xmedian 1.9x
PEG now vs peer median 3.79median 0.87 3.39median 0.43 1.59median 0.87

Financial History

Reported figures by fiscal period, placed on the calendar year (or quarter) each period ended in, so companies with different fiscal years line up.

Trailing twelve monthsCLTEVABBWI
Revenue $21.28B $17.23B $11.78B
Gross profit $12.90B $9.22B $5.13B
Operating income $3.16B $1.44B $1.73B
Net income $2.17B $508.00M $1.03B
Free cash flow $3.79B $1.24B $1.46B
R&D – $1.76B –
EPS (diluted) $2.57 $0.43 $5.08
Cash & equivalents $1.53B $4.09B $794.00M
Total debt $7.72B $16.72B $3.61B
Shares (diluted) 799.70M 1.18B 202.00M
Enterprise value $75.34B $35.12B $2.00B

All Metrics

58 metrics · best in bold

Bold marks the best reading: the lowest positive value for multiples, leverage and payout, the highest for everything else. The bar under each value is its percentile against that company's own peers. Hover a value for its rank and the peer median.

Valuation

12 metrics
MetricCLTEVABBWI
P/E 38.7x 102.6x 4.5x
P/FCF 20.9x 42.0x 3.0x
P/Operating cash flow 18.1x 29.4x 3.1x
P/S 3.7x 3.0x 0.4x
P/B 123.8x 6.5x -4.1x
P/Tangible book -95.2x 11.1x -3.5x
EV/EBITDA 22.5x 26.7x 3.3x
EV/EBIT 27.0x 45.0x 4.1x
EV/Revenue 4.0x 3.7x 0.6x
EV/FCF 22.5x 52.3x 4.9x
EV/Operating cash flow 19.6x 36.5x 5.2x
PEG (3Y EPS CAGR) 3.79 3.39 1.59

Growth

14 metrics
MetricCLTEVABBWI
Revenue growth (1Y) 5.9% 2.7% 92.8%
Revenue CAGR (3Y) 3.6% 4.1% 24.0%
Gross profit growth (1Y) 6.7% 9.7% -1.8%
Gross profit CAGR (3Y) 5.6% 9.6% -0.2%
Operating income growth (1Y) -26.1% -21.5% -6.3%
Operating income CAGR (3Y) 0.5% 46.4% -3.8%
Net income growth (1Y) -28.6% -23.3% -4.3%
Net income CAGR (3Y) 7.7% 30.3% -1.4%
EPS growth (1Y) -28.5% -30.1% 0.0%
EPS CAGR (3Y) 10.2% 30.2% 2.8%
Operating cash flow growth (1Y) 8.8% 66.0% 39.6%
Operating cash flow CAGR (3Y) 10.0% 15.2% 2.2%
Free cash flow growth (1Y) 10.0% 113.8% 37.2%
Free cash flow CAGR (3Y) 14.1% 26.7% 2.6%

Profitability

14 metrics
MetricCLTEVABBWI
Gross margin 60.6% 53.5% 43.5%
EBITDA margin 17.9% 14.0% 18.4%
Operating margin 14.8% 8.3% 14.7%
Pretax margin 13.9% 2.1% 11.2%
Net margin 9.6% 2.9% 8.7%
FCF margin 17.8% 7.2% 12.4%
Operating cash flow margin 20.5% 10.3% 11.7%
Return on equity 360.5% 6.5% –
Return on assets 13.0% 1.3% 29.5%
Return on invested capital 27.6% 5.9% 68.8%
Return on capital employed 31.2% 5.9% 51.7%
Asset turnover 1.3x 0.4x 2.3x
Cash conversion (OCF / net income) 2.0x 3.5x 1.3x
Stock comp / revenue 0.8% 1.0% 0.4%

Financial Health

11 metrics
MetricCLTEVABBWI
Debt / assets 46.1% 41.8% 70.1%
Debt / equity 12.1x 2.1x -3.4x
Net debt / EBITDA 1.6x 5.2x 1.3x
Debt / FCF 2.0x 13.5x 2.5x
Liabilities / assets 96.2% 80.1% 120.5%
Equity / assets 3.8% 19.9% -20.5%
Interest coverage 12.6x – 22.8x
Current ratio 1.0x 0.9x 1.2x
Quick ratio 0.5x 0.5x 0.6x
Cash ratio 0.2x 0.3x 0.5x
Altman Z-score 7.12 1.02 3.56

Shareholder Returns

7 metrics
MetricCLTEVABBWI
Dividend yield 2.1% – 3.7%
Net buyback yield 1.4% – -6.6%
Shareholder yield 3.6% 0.0% -2.8%
Payout ratio (earnings) 84.2% – 28.1%
Payout ratio (FCF) 48.3% – 19.8%
Dividend growth (1Y) 0.9% – 5.9%
Dividend CAGR (3Y) 1.9% – 3.9%

Analyst Estimates

Solid lines are reported fiscal-year results; dashed lines are the consensus for the years ahead. Hover a year for the analysts' high and low, and how each result compared with its estimate.

ConsensusCLTEVABBWI
Forward P/E 26.2xFY2026 22.7xFY2026 7.6xFY2026
EPS, next fiscal year $3.81FY2026 $1.96FY2026 $2.81FY2026
EPS growth, next FY +3.3%FY2026 -33.1%FY2026 -12.5%FY2026
EPS growth, the year after +10.5% +65.3% -5.3%
Revenue, next fiscal year $22.41BFY2026 $15.89BFY2026 $7.36BFY2026
Revenue growth, next FY +10.0%FY2026 -8.0%FY2026 +1.0%FY2026
Revenue growth, the year after +1.3% +16.5% +0.4%

Institutional Ownership

13F filings, quarter ended Jun 30, 2026
HoldersCLTEVABBWI
Held by institutions 83.8% 62.7% 95.8%
Institutions holding 2,019 672 465
Change in shares held, QoQ 0.0% +8.6% +1.6%
Institutions buying 921 359 245
Institutions selling 722 192 171
Buyers to sellers 1.28 1.87 1.43

Return Correlation

Daily returns, last 12 months

1.00 means two stocks move in lockstep, 0 that they move independently. Pairs below about 0.5 diversify each other.

CLTEVABBWI
CL 1.00 0.12 0.19
TEVA 0.12 1.00 0.04
BBWI 0.19 0.04 1.00

Add a Peer

Largest companies in the same industry

Related Comparisons

Frequently Asked Questions

Which is bigger, CL, TEVA and BBWI?

Colgate Palmolive (CL) is the largest by market capitalisation: Colgate Palmolive (CL) $80.86B, Teva Pharmaceutical Industries (TEVA) $50.16B, Bath & Body Works (BBWI) $4.21B.

Which stock is cheaper, CL, TEVA and BBWI?

Bath & Body Works (BBWI) trades on the lowest price-to-earnings ratio (Colgate Palmolive (CL) 39.4x, Teva Pharmaceutical Industries (TEVA) 99.1x, Bath & Body Works (BBWI) 4.1x). On next year's consensus earnings, Bath & Body Works (BBWI) is cheapest (Colgate Palmolive (CL) 26.2x, Teva Pharmaceutical Industries (TEVA) 22.7x, Bath & Body Works (BBWI) 7.6x). A lower multiple can reflect slower expected growth, so read it next to the growth figures.

Which company is growing faster?

Bath & Body Works (BBWI) grew revenue fastest over the trailing twelve months: Colgate Palmolive (CL) +5.9%, Teva Pharmaceutical Industries (TEVA) +2.7%, Bath & Body Works (BBWI) +92.8%.

Which company is more profitable?

Colgate Palmolive (CL) has the highest net margin (Colgate Palmolive (CL) 9.6%, Teva Pharmaceutical Industries (TEVA) 2.9%, Bath & Body Works (BBWI) 8.7%). On return on invested capital, Bath & Body Works (BBWI) leads (Colgate Palmolive (CL) 27.6%, Teva Pharmaceutical Industries (TEVA) 5.9%, Bath & Body Works (BBWI) 68.8%).

Which stock has performed better?

Over the past year Teva Pharmaceutical Industries (TEVA) returned the most: Colgate Palmolive (CL) +26.5%, Teva Pharmaceutical Industries (TEVA) +74.4%, Bath & Body Works (BBWI) -2.8%. Over five years, Teva Pharmaceutical Industries (TEVA) compounded fastest (Colgate Palmolive (CL) +5.0%/yr, Teva Pharmaceutical Industries (TEVA) +36.2%/yr, Bath & Body Works (BBWI) -22.2%/yr). Returns are price only, before dividends.

Which pays a higher dividend?

Only one of these companies pays a dividend: Colgate Palmolive (CL) 0.02%, Teva Pharmaceutical Industries (TEVA) 0.00%, Bath & Body Works (BBWI) -0.07%. Teva Pharmaceutical Industries (TEVA) and Bath & Body Works (BBWI) pays no regular dividend.

Which stock is riskier?

By one-year price volatility, Colgate Palmolive (CL) has been the steadiest (Colgate Palmolive (CL) 23.5%, Teva Pharmaceutical Industries (TEVA) 33.4%, Bath & Body Works (BBWI) 62.1%). Volatility measures how widely the price swings, not the risk of the business.

Which is the better stock, CL, TEVA and BBWI?

There is no single answer; it depends on what you are buying for. On the 12 head-to-head measures on this page, Bath & Body Works (BBWI) leads on 6. Business Quant does not give investment advice; use the comparison as a starting point for your own research.

Data from SEC filings, exchange prices and consensus estimates, via Business Quant. Percentile scores compare each company with its own peer group, so two companies' scores are each relative to different peers unless you rank against the whole market. Price returns exclude dividends. Nothing on this page is investment advice.